(Total Views: 591)
Posted On: 05/30/2025 3:23:59 AM
Post# of 155727
Quote:
Usually around halfway through a trial they'll compile all the current data looking at safety and efficacy and recommending trial continuance, ending the trial due to futility or changes to the trial. That data is generally known only to the DMSB
It would be a nice detail if this time we didn't choose a Gilead scientist (who is leading a trial for a competing drug) for our DMSB. Wonder how that choice got made in CD12?
(9)
(0)
